Prostate Cancer

Christopher Weight, MD, MS, discusses the current state and directions of AI and prostate cancer.

“This shows that AI analysis of routine biopsies can detect subtle signs indicating clinically significant prostate cancer before it becomes obvious to a pathologist," says Carolina Wählby, PhD.

Darolutamide plus ADT has also been approved in the US as well as in the European Union.

Kevin Shee, MD, PhD, shares findings on factors associated with recurrence and treatment failure following HIFU for prostate cancer.

The presentations featured data on the drug candidate BOTRESO for BPH and LUTS, as well as on the prostate cancer prevention drug MCS-8.

The tool is designed as a patient-facing application that can be used both during clinic visits and independently at home.

Robert B. Den, MD, outlines the exploratory applications of the Alpha DaRT technology across the prostate and bladder cancer landscapes.

Concurrent use of an ARPI with [177Lu]Lu-PSMA-617 did not improve response rates nor overall survival in patients with ARPI-refractory mCRPC.

Panelists discuss how patients currently on injectable androgen deprivation therapy can transition to oral options through an overlap period, and how stated drug interactions with androgen receptor pathway inhibitors have not been clinically significant in practice.

Timothy D. McClure, MD, outlines key findings from the PRESERVE trial, which evaluated IRE for prostate tissue ablation in patients with intermediate-risk prostate cancer.

According to the authors, these data support the value of PSMA PET/CT in the pre-salvage radiotherapy selection process.

The agent is currently being evaluated in a phase 1/2 trial.

Urologists from the University of North Carolina share insights into key advancements across the field of urologic oncology.

Timothy D. McClure outlines his approach to patient selection with focal therapy as well as how NanoKnife fits into that landscape.

The ArteraAI test is now the first and only AI-powered tool to be authorized to prognosticate long-term outcomes in patients with localized prostate cancer.

Panelists discuss how shared decision-making allows patients to test-drive oral androgen deprivation therapy options, providing flexibility for those concerned about quality-of-life impact or performance status, enabling them to start or stop treatment as needed.

Panelists discuss how patient preference plays a significant role in androgen deprivation therapy selection, with most patients preferring oral agents that offer rapid onset and quick testosterone recovery when treatment is stopped.

HIFU was shown to be an effective and tolerable treatment option for patients with intermediate-risk localized prostate cancer.

The target action date for the application is March 6, 2026.

Timothy D. McClure, MD, discusses focal therapy with IRE, specifically highlighting its benefits and limitations compared with other treatment options.

The phase 1 STRIKE-001 trial will evaluate KTX-2001 as both a monotherapy and in combination with darolutamide.

Data from the phase 2 EXTEND trial showed that the addition of metastasis-directed therapy to ADT improved measures of systemic disease control.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Panelists discuss how clinicians can confidently adapt to newer androgen deprivation therapy options like relugolix in combination therapies despite limited prospective data, emphasizing that oral agents simplify patient visits and provide equivalent testosterone suppression.

Panelists discuss how NCCN guidelines provide a framework for selecting appropriate androgen deprivation therapy (ADT) regimens across different disease states, with combination therapies now being standard of care rather than ADT monotherapy in most cases.